Abstract

The novel coronavirus pneumonia pandemic has led to bad engulf on public health worldwide. Widespread vaccination with SARS-CoV-2 vaccine (COVID-19 vaccine) has become one of the most potentially effective strategy of ending the epidemic and avoiding the public suffering from both physical and psychological pain. With weak autoimmunity and the complex body condition in different stages of treatment, cancer patients are more vulnerable and sensitive to infect in COVOD-19 pandemics. There are many data indicating that cancer patients usually obtain the higher mobidity, higher rate of the severe illness and higher fatality in COVID-19 pandemic. In that case, they are in greater need of protective measures, of which vaccination is the most convenient and widely accepted protective. Based on the existing clinical studies, this review aims to focus on the safety and efficacy of the COVID-19 vaccine in patients with cancer. After that the immunogenicity of the vaccine itself, adjuvant, doses, times of vaccinations and patient condition are listed to consider how they affet the effect of vaccine. Due to the complexity of the immune function of cancer patients, COVID-19 vaccination in cancer patients is extremely critical to protect from COVID-19 pneumonia, so large-scale clinical studies and real-world research data are still needed to develop a more refined and appropriate vaccination program to achieve better protection of oncology patients.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call